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Abstract
Purpose [11C]Palmitate PET can be used to study myocar-
dial fatty acid metabolism in vivo. Several models have
been applied to describe and quantify its kinetics, but to
date no systematic analysis has been performed to define
the most suitable model.
Methods In this study a total of 21 plasma input models
comprising one to three compartments and up to six free
rate constants were compared using statistical analysis of
clinical data and simulations. To this end, 14 healthy
volunteers were scanned using [11C]palmitate, whilst
myocardial blood flow was measured using H2
15O.
Results Models including an oxidative pathway, represent-
ing production of 11CO2, provided significantly better fits
to the data than other models. Model robustness was
increased by fixing efflux of 11CO2 to the oxidation rate.
Simulations showed that a three-tissue compartment model
describing oxidation and esterification was feasible when
no more than three free rate constants were included.
Conclusion Although further studies in patients are re-
quired to substantiate this choice, based on the accuracy of
data description, the number of free parameters and
generality, the three-tissue model with three free rate
constants was the model of choice for describing [11C]
palmitate kinetics in terms of oxidation and fatty acid
accumulation in the cell.
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Introduction
The myocardium relies on several sources of energy,
including polysaccharides (sugar) and short and long fatty
acids. Measuring kinetics of these compounds can give
valuable information about myocardial function under
various conditions [1, 2]. Uptake and utilization of
polysaccharides can be measured using FDG. The kinetic
behaviour of FDG is well understood and can be described
accurately by an irreversible two-tissue compartmental
model [2, 3]. For studying oxidation of other energy
sources (MVO2) of the heart, the short-chain fatty acid
[11C]acetate is often used [4, 6, 7]. Although kinetics of this
tracer were originally studied using a six-compartment
model, the limited time resolution of a PET study forced a
reduction to a simplified two-tissue compartment model
describing uptake (and back diffusion) and (irreversible)
oxidation of the tracer [6, 7].
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Finally, [11C]palmitate can be used to study uptake and
utilization of long-chain fatty acids, which play a dominant
role in delivering energy to the heart. Since fatty acid
metabolism [8] is affected by a number of pathophysiolog-
ical conditions, [11C]palmitate has been used to study
myocardial metabolism in various diseases such as viral
infections and diabetes [5, 10]. Most studies involving
[11C]palmitate used semiquantitative analyses to describe
its kinetics. Tracer washout is commonly described using a
biexponential function with a rapid phase reflecting fast
oxidation of fatty acid in the mitochondria and a slower
phase, appearing later, representing incorporation of
extracted fatty acids into neutral lipid pools [10]. However,
a simpler single-exponential model, only describing oxida-
tion of the tracer has also been used [11].
A possibly more accurate three-tissue compartmental
model (hence described by three exponentials), in which
uptake of palmitate in cytosol, beta-oxidation in mitochon-
dria and incorporation of fatty acid into neutral lipids is
described, has been proposed by Bergmann et al. [9]. The
model was validated using dogs under several conditions
and subsequently used to assess altered myocardial fatty
acid metabolism associated with cardiomyopathy in
patients [12]. Although the proposed model corresponds
with known pathways of fatty acids and therefore is a
valid model, to date no details about accuracy, reproduc-
ibility or identifiability of individual pathways have been
reported.
In the present study, simulations and actual PET data
from healthy controls were used to evaluate the above-
mentioned three-tissue compartment model, together with
other, simplified, models describing [11C]palmitate kinetics.
Although final model choice will also depend on physio-
logical relevance, parameter identifiability of the model is a
first and mandatory criterion in model choice and was the
overall aim of this study.
Materials and methods
Patients
A group of 14 healthy men (Table 1), aged 53.7±6.0 years,
were recruited by advertisements in local newspapers.
Healthy men without complaints or any history of cardio-
vascular disease were eligible. Inclusion criteria were blood
pressure not exceeding 140/90 mmHg, body mass index
<32 kg/m2, and normal glucose tolerance. Exclusion criteria
were any clinically significant disorder, dyslipidaemia,
requiring pharmacological treatment, or the use of any
prescribed drug. Subjects were screened, including history,
physical examination, echocardiogram, and fasting blood
and urine analyses. Normoglycaemia was determined using a
75-g oral glucose tolerance test. Written informed consent was
obtained from all participants. The protocol was approved by
the local Medical Ethics Committee, and performed in full
compliance with the Declaration of Helsinki.
Production of PET tracers
[11C]Palmitate was synthesized according to a modified
method previously described by Welch et al. [13] and using
nuclear interface equipment. Radiochemical purity was
>97%.
Study procedures
Subjects arrived at the PET facility at 08.00 a.m. after an
overnight fast. They had been instructed to abstain from
alcohol, caffeine-containing beverages and physical exercise
for 48 h prior to PET scanning. For six subjects arterial and
venous samples taken during the [11C]palmitate scan were
compared with regard to specific activity concentrations
including metabolites. Since no significant difference was
found in these blood values all other subjects received only
an indwelling venous catheter in an antecubital vein.
During all procedures patients were monitored by telemetry
and blood pressure was measured at 5-min intervals. Blood
samples were collected during both scans at predefined
intervals to measure plasma substrate (glucose, nonesteri-
fied fatty acids, lactate, triglycerides) and insulin levels. In
addition samples for plasma/whole-blood ratios and 11CO2
concentrations were drawn and analysed immediately.
PET scanning
All scans were performed using an ECAT EXACT HR+
scanner capable of 2-D and 3-D acquisition (Siemens/CTI,
Knoxville, TN) [14, 15]. A 10-min transmission scan, using
three rotating 68Ge line sources, together with sinogram
Table 1 Subject characteristics (n=14)
Characteristic Mean±SD
Age (years) 53.7±6.0
Body mass index (kg/m2) 27.5±2.6
Waist circumference (cm) 102±7.6
Blood Pressure (mmHg) 117±13/70±8
Total cholesterol (mmol/l) 4.9±0.7
LDL cholesterol (mmol/l) 3.1±0.6
HDL cholesterol (mmol/l) 1.3±0.3
Triglycerides (mmol/l) 0.86±0.3
Plasma glucose (mmol/l) 5.3±0.4
Nonesterified fatty acids (mmol/l) 0.43±0.14
Lactate (mmol/l) 0.8±0.2
Insulin (pmol/l) 30±14
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windowing, was performed after subject positioning at the
cardiac level. Next, to measure myocardial blood flow
(MBF), 1,100 MBq H2
15O dissolved in 5-ml saline was
injected intravenously as a bolus, followed by a 40-ml saline
flush at a rate of 4 ml/s. A dynamic emission scan was
acquired consisting of 40 frames with variable frame length
for a total duration of 10 min (12×5, 12×10, 6×20, and
10×30 s). This scan was performed in 2-D mode to prevent
large dead time effects at the beginning of the scan [16].
After 10 min to allow for decay of residual 15O, fatty acid
imaging was performed using [11C]palmitate. An intravenous
bolus of 180 MBq was followed immediately by a 30-min
dynamic emission scan in 3-D mode for increased sensitivity.
This scan was divided into 33 frames (6×5, 6×10, 3×20,
5×30, 5×60, and 8×150 s). All emission data were corrected
for physical decay, dead time, scatter, randoms, and (mea-
sured) photon attenuation. Image reconstruction was per-
formed using filtered back projection (FBP) with a Hanning
filter at 0.5 of the Nyquist frequency, resulting in a spatial
resolution of about 7 mm full-width at half-maximum. In
addition a 10 to 30-min sum image was reconstructed with
OSEM.
In order to generate myocardial time–activity curves
(TACs), regions of interest (ROIs) were defined on resliced
short-axis [11C]palmitate images using the OSEM recon-
structed summed image from 10 to 30 min. Six basal ROIs,
six distal ROIs and one apical ROI were defined as
described previously [17]. Additional ROIs were defined
in left ventricular chambers for image-derived input
functions (IDIF). An example of ROI placement is shown
in Fig. 1. Myocardial segments exposed to liver spill-in
were omitted from the analysis of [11C]palmitate scans,
whilst all other ROIs were grouped for further analysis. All
ROIs were projected onto the dynamic H2
15O image data to
generate water TACs.
Plasma input
An [11C]palmitate plasma input function was generated by
multiplying the image-derived left ventricle TAC by the
plasma to whole blood ratio and by correcting for the
fraction of 11CO2 as obtained from the venous samples. As
these corrections were based on a limited number of
manually drawn blood samples, spline interpolation was
used to correct values at every time-frame of the PET scan.
Kinetic models
Myocardial blood flow
H2
15O data were fitted to a standard four-parameter, single-
tissue compartment model including MBF, perfusable tissue
fraction and spill-over fractions from both ventricles [18].
The left ventricular cavity TAC was used as input function
to the model.
[11C]Palmitate fatty acid metabolism
A total of 21 different models with different combinations
of compartments, rate constants and constraints were
investigated. The models were divided into four families
depending on the number and type of compartments that
were included. Within a family of models, the number of
rate constant and constraints were varied (Table 2).
For family 1, one compartment was used to describe
uptake of [11C]palmitate from plasma into tissue (kp1), and
washout from tissue back to plasma (k1p). This model does
not distinguish between back diffusion of [11C]palmitate or
efflux of 11CO2. Family 2 included both a free or interstitial
compartment and a compartment describing turn-over of
free fatty acids into neutral lipids and amino acids, with rate
constants kp1, k1p, k12, k21 describing transfer rates between
compartments. In one implementation (model 2B), the
back-diffusion process (k21) was omitted, limiting the total
number of free parameters to three.
Although also constructed from two compartments,
models from family 3 differed from family 2 models in
terms of metabolic pathways. Instead of (slow) turn over of
free fatty acids, it included a mitochondrial compartment
with k13 describing transport of [
11C]palmitate into the
mitochondria and k3p efflux of
11CO2 into the blood.
Different implementations were obtained by omitting k1p
(model 3B), whilst further reduction of the number of free
rate constants was obtained by fixing k3p to a value
proportional to flow (MBF/Vb, with Vb=0.1, being the
Fig. 1 Short axis [11C]palmitate image of the myocardium. Shown is
a summation of frames taken from 10 to 30 min and the ROIs used for
extraction of tissue and blood TACs
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blood volume of the myocardium; models 3A(1) and 3B
(1)) or by imposing k3p=k13 (models 3A(2) and 3B(2)).
The largest family of models (family 4) included all
three compartments introduced by Bergmann et al. [9].
Reduction of the number of free parameters was accom-
plished by omitting either or both k1p and k21 (models 4C,
4B and 4D, respectively). In addition, further modifications
(reductions) were obtained by fixing k3p in a similar
manner as for family 3. Using family 4 models, myocardial
fatty acid uptake (MFAU), myocardial fatty acid oxidation
(MFAO) and myocardial fatty acid esterification (MFAE)
can be estimated separately (see below).
Implementation
For every model a set of differential equations can be
defined. Its analytical solution can then be fitted to
myocardial PET data, yielding estimates of the various
Table 2 Overview of all models evaluated, categorized into four families, depending on number (1 to 3) and structure of compartments
Family 1 Family 2 Family 3 Family 4
Model 1
2 FRC: kp1, k1p
Model 2A
4 FRC: kp1, k1p, k12, k21
Model 3A
4 FRC: kp1, k1p, k13, k3p
Model 4A
6 FRC: kp1, k1p, k12, k21, k 13, k3p
Model 2B
3 FRC: kp1, k1p, k12
Models 3A(1),(2)
3 FRC: kp1, k1p, k13
k3p fixed
Model 4A(1),(2)
5 FRC: kp1, k1p, k12, k21, k 13
k3p fixed
Model 3B
3 FRC: kp1, k13, k3p
Model 4B
5 FRC: kp1, k1p, k12, k 13, k3p
Model 3B(1),(2)
2 FRC: kp1, k13
k3p fixed
Model 4B(1),(2)
4 FRC: kp1, k1p, k12, k 13
k3p fixed
Model 4C
5 FRC: kp1, k12, k21, k 13, k3p
Model 4C(1),(2)
4 FRC: kp1, k12, k21, k 13
k3p fixed
Model 4D
4 FRC: kp1, k12, k 13, k3p
Model 4D(1),(2)
3 FRC: kp1, k12, k 13
k3p fixed
1 2
3
p1
3
1 2p1p p
Arrows indicate rate constants with grey arrows being omitted in some of the models, and p indicates plasma. FRC is the number of free
parameters, excluding spill over factors that are present in all models. Depending on the model k3p can be fixed to (1) MBF/Vb, or (2) k13.
Eur J Nucl Med Mol Imaging (2009) 36:966–978 969
parameters. As all models can be deduced from the
description of model 4A by setting specific parameters to
zero (or to fixed values), only the solution of model 4A is
given. Similar to the suggestion of Degrado et al. [19], this
model can be solved and described by three exponentials
[19]:
CPET tð Þ ¼ 1 Slvð Þ a1eb1t þ a2eb2t þ a3eb3t
  Cp tð Þ þ SlvClv tð Þ
b1 ¼ 12 k1p þ k12 þ k21 þ k13
 þ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
k1p þ k12 þ k21 þ k13
 2  4 k1pk21 þ k21k13
 q 
b2 ¼ 12 k1p þ k12 þ k21 þ k13
 
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
k1p þ k12 þ k21 þ k13
 2  4 k1pk21 þ k21k13
 q
 
b3 ¼ k3p
a1 ¼ k21b1ð Þk13kp1k3pb1ð Þ b2b1ð Þ þ
k12kp1
b2b1ð Þ þ
k21b1ð Þkp1
b2b1ð Þ
a2 ¼ k21b2ð Þk13kp1
k3pb2ð Þ b1b2ð Þ þ
k12kp1
b1b2ð Þ þ
k21b2ð Þkp1
b1b2ð Þ
a3 ¼
k21k3pð Þk13kp1
b1k3pð Þ b2k3pð Þ
ð1Þ
CPET(t) is the measured [
11C]palmitate TAC, Cp(t) the
plasma input, Clv(t) the blood TAC taken from the left
ventricle, Slv the unknown spill-over of arterial signal into
the myocardium, and k1p, kp1, k12, k21, k13 and k3p are the
rate constants as described above. Since spill-over from the
right ventricle was found to be negligible, it is not included
in the model. The fraction of tissue TAC representing real
myocardial tissue activity (perfusable tissue fraction, PTF)
cannot be estimated independently from kp1 and was therefore
estimated as (1−Slv). This was based on the finding that this
specific relationship between the spill-over factor Slv and PTF
was present in the H2
15O studies and the assumption that the
underlying physics determining these factors (myocardial
wall movement, vascularity, limited resolution) were compa-
rable in both studies. The macroparameters MFAO and
MFAE were defined according to Bergmann et al. [9]:
MFAE ¼ CNEFA  kp1k12k1p þ k12 þ k13 ð2Þ
MFAO ¼ CNEFA  kp1k13k1p þ k12 þ k13 ð3Þ
andMFAU equals the sum ofMFAO andMFAE.CNEFA is the
concentration of nonesterified free acids in blood (in
millimoles per gram). In brief, fitting Eq. 1 to the [11C]
palmitate data directly yielded the parameters kp1 … k3p,
from which the macroparameters could be calculated. When
applying models that did not include backflow from
compartment 1 to plasma, k1p was set to zero in Eqs. 2 and 3.
Model analysis
All models were fitted to CPET(t) using a nonlinear least-
squares optimization process based on the Levenberg-
Marquart algorithm [20]. Results were analysed using the
following criteria:
Residual errors The residual or sum of squared errors was
used to describe how well the estimated curve fitted to the
data. Values averaged over all subjects are reported.
Akaike information criterion (AIC) Similar to the residual
errors, except that penalties are given for the number of
parameters used. AIC includes the effect that models with a
larger number of free parameters are more likely to find
solutions that are closer to the data, but yield parameter
estimates with lower confidence.
Average parameter values For each model, average values
and standard deviations of each parameter were determined
over the entire group of normal subjects. As it concerns a
relatively homogeneous group of volunteers, the standard
deviation, SD, of the distribution of values within the group
is some indication of the precision of the estimate.
Furthermore, the standard error, SE, in parameter estimation
was calculated based on the Jacobian that results from the
fitting procedure for each subject and parameter. SE is a
measure of robustness of the parameter estimation. SE
values averaged over all subjects are reported.
Sensitivity analysis The relative change in model outcome
or TAC resulting from a change in an individual parameter
is indicative of how accurately the parameter can be
estimated. Sensitivity functions for each parameter were
generated by determining the change in model outcome
resulting from a 1% change in the parameter [21, 22]. First,
typical arterial TACs (Cp(t) and Clv(t)) were generated by
averaging the measured curves over all studies. These were
970 Eur J Nucl Med Mol Imaging (2009) 36:966–978
then used to generate tissue TACs. If each of the sensitivity
functions for the parameters are sufficiently different over
time, then the parameters are identifiable. To test the ability
of the model to estimate parameters independently, we used
identifiability analysis of the sensitivity curves to generate a
sensitivity matrix as previously described [21, 22]. Each
element in the sensitivity matrix represents the correlation
between any two parameters to produce a change in the
output of the model. Pairs of parameters within the
correlation matrix elements close to ±1 will have estimates
that covary considerably and are therefore difficult to
estimate independently. Furthermore, the required length
of the experimental data collection and analysis may be
indicated from the sensitivity functions. To evaluate the
impact of lengthening the scan duration, sensitivity curves and
correlation matrices were also generated for a 45-min scan.
Monte Carlo simulations These were performed to assess
accuracy of estimated MFAU, MFAE and MFAO over a
wide range of parameter values. For every model a set of
100 tissue TACs was generated using randomly selected
parameters. Simulations were performed with and without
addition of Gaussian noise. In reality, the noise level in the
ROI depends on many factors including ROI, acquisition
and reconstruction parameters and cannot be measured
directly due to unknown real activity distribution and local
heterogeneity. Therefore, noise level was based on total
(non-decay corrected) trues T per frame, with a coefficient
of variation equalling α/√T. For all simulations α was
chosen such that the residuals of the model fits to the
simulated data were similar to those found in the patient
data using the most precise model (4A), which is the best
estimate of the true TAC. Subsequently the simulated tissue
TACs were fitted to the models to yield estimated parame-
ters. Since this was done over the full range of parameter
values, scatter plots of true vs. estimated parameter values
could be generated, illustrating the confidence of the
estimated parameter. For every simulation the model used
for parameter estimation was the same model as that used for
generating the TACs. Ideally, for a noiseless situation and a
suitable model, a perfect correlation between simulated and
estimated parameters is to be expected.
Results
Myocardial blood flow
MBF values averaged 0.81±0.21 ml/ml per minute. In
relevant models (Table 2), these MBF values were used to
fix the outflow of 11CO2 from mitochondria to the vascular
space described by parameter k3p.
[11C]Palmitate
In Fig. 2 (top) a typical example is shown of a correction
curve (based on manual sample data) used to translate the
image-derived whole-blood curve into a plasma input curve
that is corrected for differences in plasma and whole-blood
concentrations and for the presence of 11CO2. A myocardial
TAC with associated fits from a variety of models is also
depicted in Fig. 2. For all models, the average left
ventricular spill-over fraction Slv was 0.18±0.05. A high
correlation (R2=0.998, data not shown) was found between
spill-over factors estimated with different models.
Residual errors Table 3 shows average residual errors of all
models included in the study. In general, the error decreased
with increasing number of free parameters. As compared to
the single-compartment model (family 1), inclusion of the
mitochondrial compartment (compartment 3) improved the
quality of the fits dramatically (families 3 and 4), except
when k3p was fixed to MBF/Vb. This improvement was not
seen when only the compartment representing the slow
turnover pool was included (family 2). Lowest residual
errors were obtained when all three compartments were
included (family 4), although differences between families
3 and 4 were very small. Fixing k3p to a value proportional
to MBF (i.e. to MBF/Vb) resulted in much larger errors than
fixing it to k13.
Akaike Information Criterion In Table 3 the preference for
each model based on AIC values is also given. In addition
to the residual error, AIC also takes into account the
number of free parameters in the model and therefore it can
be regarded as a more sensible measure of goodness of fit.
In 50% of the subjects, model 3B(2) was the preferred
model.
Average parameter values Table 4 shows average values
and standard deviations (SD) of the various parameters
across the subjects for most models. In addition, mean
standard errors (SE) of the fitted parameters are provided.
As residual error and AIC analyses had already indicated
preference for models in which k3p was fixed to k13, models
in which k3p was fixed to MBF/Vb were excluded from
further analysis. From Table 4 it can be seen that kp1 can be
estimated with high precision, nearly independent of model
choice. For all other parameters, actual parameter values
(and spread, i.e. both SD and SE) heavily depended on
model choice. This is especially the case for k21 and k12,
and to a lesser extent, for k13. In concordance with this, all
models that consisted of more than three free rate
constants yielded at least one parameter with an SE that
was an order of magnitude larger than the average
parameter value.
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Sensitivity analysis As input for the sensitivity analysis,
average clinical parameters were used together with average
curves for plasma input, and left and right ventricles. Figure 3
shows sensitivity curves for four models (3B(2), 4D(2), 4C
(2) and 4A(2)). Since the curves of the various parameters of
models 3B(2) and 4D(2) differed significantly, it was
expected that these parameters could reliably be estimated
independently. For models 4A(2) and 4C(2), however, the
shape of the curves for parameters k1p, k12, k21 and k13 were
very similar. Correlation values between parameters are
given in Table 5. For model 4A(2), there was a high level
of correlation between all parameters except kp1. This
suggests that it would be difficult to obtain independent
estimates of these parameters using model 4A(2). Similarly,
k21 and k13 were highly correlated with k12 for model 4C(2).
In contrast, for model 4D(2) all correlations were smaller
than 0.9, yielding better conditions to independently estimate
its parameters, although the independence of k13 remains
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Fig. 2 Top Example of a typical correction curve (together with
measured manual sample data) for transferring an image-derived
whole-blood curve into a plasma input curve corrected for the
presence 11CO2. Bottom Example of myocardial [
11C]palmitate data
(dots) together with best fits (lines) using various models
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somewhat dubious in this analysis. Also shown in Table 5
are the correlation values for a 45-min scan. Increasing the
scan length by 50% had a positive effect on the estimation of
k13 using the 4D(2) model only.
Monte Carlo simulations As input, average blood curves as
obtained from the clinical study were used. Scatter plots are
given in Fig. 4 for noiseless curves. From the scatter plots,
Pearson correlation coefficients were calculated for simu-
lations both without and with gaussian noise (Table 6). For
all models, parameter kp1 and changes in MFAU could be
detected with high accuracy. When using model 4C(2) and
especially 4A(2), significant uncertainties in MFAO esti-
mation were found even in the noise-free situation. MFAE
could only be estimated reliably using model 4D(2), while
4C(2) again yielded large uncertainties. In addition, using
model 4A(2) MFAE contained large biases. Interestingly,
the effects of noise on the confidence of parameter estimate
were small, probably due to the use of large ROIs (Table 6).
Direct comparison of models 3B(2) and 4D(2)
In order to investigate to what extent a three-tissue
compartment model could be used for analysing data, a
direct comparison was made between two-tissue model 3B
(2) and three-tissue model 4D(2). The first model was the
most preferred amongst all models in the AIC analysis,
whilst the latter was preferred amongst models of family 4.
In addition, model 4D(2) was the only model that showed
promising results in the sensitivity and Monte Carlo
analyses. Again, using AIC, a direct comparison was made
between models 3B(2) and 4D(2) across all 14 subjects.
According to the AIC, model 3B(2) was preferred in eight
subjects and model 4D(2) in six (Fig. 5). Hence, the total
population was split into a ‘3B(2) group’ with eight subjects
and a ‘4D(2) group’ with six subjects. As well as this, all 14
subjects were analysed with model 4D(2), so that for every
subject in both groups a k12 value was found. For the ‘3B(2)
group’ the average value of k12 was 0.005±0.005 min
−1. In
contrast, for the ‘4D(2) group’ it was 0.024±0.013 min−1
(Fig. 5). Hence, as could have been expected, model 4D(2)
appeared to be the model of choice when k12 is relatively
high. Importantly, using model 4D(2) for all subjects had
negligible effects on the estimation of kp1 (R
2=0.999) and k13
(R2=0.989), as shown in Fig. 5.
Discussion
This study addressed possible kinetic models and their
potential to describe uptake of [11C]palmitate in the
myocardium. The suitability of a kinetic model depends
on several factors. Based on biochemical pathways of the
tracer, as known from in vitro or animal studies, kinetics
can be expressed adequately by more comprehensive tracer
compartment models. For [11C]palmitate, such a model
typically comprises ten compartments with associated rate
constants, which clearly would provide an adequate
description of tracer kinetics. In order to use a model in
PET studies, however, it is usually necessary to simplify the
compartmental structure to meet the limited information
contained within dynamic PET data. Ideally, but not
possible in human studies, the outcome of a model should
then be compared with direct measurement of the kinetics
at the organ or cell level. As both physiological description
and clinical consequences of [11C]palmitate model choice
have previously been discussed in detail [9, 11, 23, 24], the
present study focused on the applicability of these models
within spatial and temporal limitations of the PET data. To
assess how many parameters could be determined from
human [11C]palmitate studies, models of different levels of
complexity were compared systematically, in each case
relating the model to the underlying physiology [25–27].
Previously, a three-tissue compartment model has been
proposed, describing uptake, oxidation and esterification of
[11C]palmitate in the myocardium, which was evaluated in
dogs [9]. Although it is well known that actual metabolic
pathways are much more complex, it would in theory be
reasonable to describe the various pathways using this
simplified model, given the limited kinetic information of
Table 3 Average residual error for each model and number of
preferred fits per model according to the AIC
Model Average residual
error (×104)
Number of preferred fits
according to AIC
1 69 1
2A 69
2B 69 1
3A 44
3A(1) 69
3A(2) 45 2
3B 45 1
3B(1) 69
3B(2) 52 7
4A 44
4A(1) 69
4A(2) 44
4B 43
4B(1) 69
4B(2) 43
4C 43
4C(1) 69
4C(2) 45
4D 44
4D(1) 69
4D(2) 44 2
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the data. However, even a three-tissue compartment model
with a relatively large number of fit parameters (up to
seven) can be challenging. As a matter of fact, to our
knowledge, no other PET tracer kinetic model with so
many parameters has successfully been used before.
Therefore, in the present study, both PET data from
volunteers and simulated data were used to investigate
whether a three-tissue compartment model could be used in
practice. As potential alternatives to the three-tissue
compartment model, both single and two-tissue (i.e. further
simplified) compartment models were included in order to
perform a formal assessment of the number of identifiable
compartments.
Since there is no gold standard for in vivo determination
of fatty acid metabolism in the heart, no direct accuracy of
model outcome could be determined. Some data on fatty
acid metabolism in the heart has been published however,
using a more simplified biexponential model [10]. For
comparison, the patient data in this study were also
analysed with the biexponential model: average uptake
indices (±SD) were 0.08±0.02 vs. 0.11±0.01, and clearance
half-times were 19.1±3.1 min vs. 17.6±1.6 min for this
study and the study by Knuuti et al. [10], respectively.
Preferred model
Although a number of mathematical methods were applied
to investigate applicability of models, their conclusions
were concordant. AIC and standard error analysis both
showed that models including more than three free rate
constants yielded parameters with very low confidence,
which was due to strong interparameter correlation, as
indicated by the sensitivity analysis. Monte Carlo analysis
finally confirmed this finding by showing that noise had
little effect on parameter identifiability.
Sources of error
Simplified models with a limited number of free rate
constants are likely to be more robust for parameter
estimation, but they also yield less information about
underlying physiology. For example, the outcome of a
single-tissue compartment model is restricted to influx and
egress of [11C]palmitate and does not provide a separate
assessment of the oxidative pathway, possibly obscuring
sources of altered fatty acid metabolism. Although unlikely,
11CO2 itself could hypothetically be taken up from blood
into tissue. This could be investigated using 11CO2 as a
primary tracer [28]. Furthermore, additional studies are
needed to assess whether other metabolites are produced
and, if so, how sensitive the model is to the presence of
these metabolites.
For the clinical data possible sources of error were
similar to those in PET studies in general. Although
quantification of PET data is never a matter of course,
scanner and reconstruction methods used in this study were
Table 4 Average values of fitted parameters for most models
Parameter Model
1 2A 2B 3A 3A(2) 3B 3B(2) 4A 4A(2) 4B 4B(2) 4C 4C(2) 4D 4D(2)
kp1 Average 0.19 0.19 0.19 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17
SD 0.04 0.04 0.04 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03
SE 0.004 0.01 0.01 0.01 0.01 0.01 0.003 0.05 0.02 0.01 0.01 0.01 0.01 0.01 0.004
k1p Average 0.06 0.06 0.06 0.02 0.02 0.02 0.02 0.02 0.02
SD 0.02 0.02 0.02 0.02 0.02 0.03 0.03 0.02 0.02
SE 0.002 0.01 0.01 0.05 0.02 0.5 0.14 0.06 0.03
k12 Average 0.00 0.00 0.15 0.09 0.01 0.01 0.33 0.18 0.02 0.01
SD 0.00 0.00 0.11 0.13 0.01 0.01 0.57 0.25 0.04 0.01
SE 0.02 0.08 26 2.2 0.18 0.01 1.2 0.1 0.11 0.008
k21 Average 0.09 0.50 0.55 0.20 0.13
SD 0.12 0.38 0.62 0.20 0.17
SE >1,000 18 7.8 1.4 0.57
k13 Average 0.15 0.10 0.09 0.12 0.16 0.12 0.15 0.10 0.30 0.16 0.23 0.13
SD 0.11 0.04 0.03 0.03 0.07 0.03 0.07 0.04 0.36 0.05 0.25 0.03
SE 4.0 0.02 0.01 0.003 13 0.6 6.9 0.04 4.0 0.04 1.45 0.008
k3p Average 0.10 0.4 0.12 0.12 0.14 0.13
SD 0.05 0.5 0.04 0.03 0.04 0.06
SE 4.0 0.16 6.0 6.9 3.3 1.43
The standard deviation (SD) represents the spread across subjects. The average (across subjects) standard error (SE) gives the estimated
uncertainty of individually fitted parameter values.
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well validated and can be regarded as proven technology.
To counteract the effect of limited resolution and cardiac
wall movement, spill-over and perfusable tissue factors
were included in the model. Furthermore, all studies were
manually checked by comparing the position of the
myocardium through the dynamic which revealed no
patient movement. The impact of noise on the analysis
was minimized by using summed ROIs. The Monte Carlo
simulations included a similar noise level to that in the
clinical data, and showed no large detrimental influence of
noise.
For the simulations a possible source of error could have
been a physiologically incorrect model or wrong choice of
parameters. In order not to give undue preference to a
model, for the Monte Carlo simulated data the same model
was used as for the parameter estimation of these data
(matched models), making the clinical validity of the model
less relevant. Hence, errors in simulated parameter estima-
tion would have come from either simulated noise or
interdependency of variables. The average parameter values
used for simulation were based on the clinical results. Since
these were unreliable for some models and could have
varied significantly, a range of values was used in the
scatter analysis to try to include all possible situations.
Oxidation and esterification
The major finding from the present systematic model
analysis is that an oxidative pathway should be incorporat-
ed when describing [11C]palmitate metabolism. This is
underscored by the fact that model 3B(2), a two-tissue
compartment model with free parameters kp1 and k13, was
preferred over the single-tissue compartment model 1 with
free parameters kp1 and k1p, although both models had an
Table 5 Correlation or covariance values between parameters as
derived from sensitivity analysis. Values in parentheses are derived
from analysis of a prolonged 45-min scan
3B(2) 4A(2) 4C(2) 4D(2)
kp1 – k1p 0.42 (0.40)
kp1 – k12 0.33 (0.33) 0.30 (0.33) 0.14 (0.14)
kp1 – k21 0.26 (0.28) 0.22 (0.25)
kp1 – k13 0.28 (0.31) 0.28 (0.29) 0.44 (0.46) 0.30 (0.33)
k1p – k12 0.99 (0.99)
k1p – k21 0.96 (0.98)
k1p – k13 0.97 (0.98)
k12 – k21 0.99 (0.99) 0.96 (0.96)
k12 – k13 1.0 (1.0) 0.95 (0.95) 0.84 (0.70)
k21 – k13 1.0 (1.0) 0.84 (0.85)
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Fig. 3 Sensitivity curves for
various models
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equal number of free parameters. In order to reduce the
number of free parameters, Bergmann et al. proposed fixing
k3p to MBF/Vb that could be derived from an independent
MBF measurement. Although the found MBF values are in
concordance with the generally found average and range of
MBF values [29], in the present study such an approach
did not yield optimal fits. This could have been due to
incorrect assumptions about the value of Vb. However, no
correlation between MBF as determined with H2
15O and
k3p as determined with models 4A, 4B, 4C or 4D (best
correlation R2=0.28) could be found, suggesting that if k3p
is equal to MBF/Vb, Vb itself is not constant. Therefore
physiological variation in Vb, or even a coupling between
MBF and Vb, could be expected. Hence, although in
principle, incorporating additional information to the
model could increase reliability, the present results raise
doubts as to whether MBF/Vb with a constant Vb could be
used to independently determine k3p, at least in healthy
human subjects.
Monte Carlo simulations suggested that the metapara-
meters describing uptake, oxidation and esterification could
be estimated accurately using model 4D(2), the simplest
three-tissue compartment model. Analyses using model 4C
(2) indicated that adding just one additional free parameter
(compared with model 4D(2)) significantly decreased the
confidence of metaparameter estimation. This is illustrated
by the spread seen in Fig. 4 for model 4C(2), where ideal
conditions were used (i.e. no noise in the simulated data).
The limited value of all models of family 4 other than
model 4D(2) is underlined by the sensitivity analyses that
showed large correlations between different parameters
even when the scan length was increased by 50% (Table 5).
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Fig. 4 Results of noise-free simulations showing the accuracy of the estimated metaparameter vs. the true value for three models. Top model 4A
(2), centre model 4C(2), bottom model 4D(2)
976 Eur J Nucl Med Mol Imaging (2009) 36:966–978
Although model 4D(2) could be used to describe [11C]
palmitate kinetics, in a small majority of all subjects (8 out
of 14, 57%) model 3B(2) was preferred, probably because
parameter k12 was negligible in this group, and hence, there
was no added value in applying model 4D(2). This is in
agreement with the general situation that free fatty acid in
healthy subjects is primarily oxidized rather than accumu-
lating in the myocardial cell. Although there is no direct
argument for using the three-tissue compartment model for
this specific group, the comparison between models 3B(2)
and 4D(2) showed that estimated values of the other
parameter were hardly affected, and therefore it could still
be used without loss of precision. On the other hand, if
model 3B(2) were to be used for the group in which model
4D(2) was preferred, esterification wrongly could be
ignored according to the AIC.
An important application of [11C]palmitate will be in
subjects with heart disease with possibly altered metabo-
lism as compared to the subjects with healthy aerobic hearts
included in this study. It is likely that the esterification
pathway is even more pronounced in some patient groups,
such as patients with type 2 diabetes mellitus. In such
patients, the use of model 4D(2) is recommended, as it
allows for esterification without compromising the results
when this pathway is negligible.
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Fig. 5 Top left Direct compari-
son between models 3B(2) and
4D(2) in terms of preferred
model according to the AIC. Top
right Average k13 as determined
using model 4D(2) for the
groups of volunteers in which
models 3B(2) and 4D(2) were
preferred. Bottom Correlation
between kp1 values and between
k13 values, both as obtained with
models 3B(2) and 4D(2)
Table 6 Pearson correlation coefficients from the Monte Carlo
simulations shown in Fig. 4, indicating confidence and bias with
which parameters can be estimated under noise-free and realistic noise
(in parentheses) conditions
3B(2) 4A(2) 4C(2) 4D(2)
kp1 1.0 (1.0) 1.0 (0.99) 1.0 (1.0) 1.0 (1.0)
k1p 0.93 (0.91) – –
k12 0.17(0.13) 0.24 (0.28) 1.0 (0.93)
k21 0.73 (0.49) 0.82 (0.66) –
k13 1.0 (1.0) 0.81(0.79) 0.99 (0.97) 1.0 (0.97)
MFAU 0.95 (0.95) 1.0 (1.0) 1.0 (1.0)
MFAO 0.85 (0.77) 0.85 (0.84) 1.0 (0.99)
MFAE 0.66 (0.60) 0.83 (0.80) 1.0 (0.99)
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Conclusion
The optimal model for analysing [11C]palmitate data is a
three-tissue compartment model in which three rate
constants need to be fitted. Inclusion of an oxidative
pathway in the model is essential and best fits were
obtained by fixing the efflux rate of 11CO2 to the oxidation
rate. Inclusion of a (slow) esterification compartment had
less impact, improving fits in about half of the normal
subjects. Nevertheless, inclusion of this compartment is
recommended as it had only a minor impact on the
reliability of the other parameters, whilst allowing for more
pronounced esterification, which is likely to be present in
some patient groups.
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